- EXOGENIS For Clinics & Partners
Add a controlled delivery step to existing clinic workflows
Exogenis is designed to fit into selected aesthetic and dermatology clinic workflows as repeatable, injection-free delivery step for post-procedure recovery and between-treatments maintanance.
workflow-compatible
Designed to fit after selected procedures such as laser, RF, micro needling, peels, or other clinic-led skin treatments.
repeat-use protocols
Support structured between-treatement care and clinic-guided maintenance.
commercial signal
Pilot use will test workflow fit, repeat use, behaviour, reorder intent, and clinic economics.
Clinic-guided maintenance protocol
A structured approach for professional use, patient continuity, and repeat-use validation
01. IN CLINIC
Introduced after selected treatments
ExoGenis can be positioned as a professional delivery step after selected aesthetic procedures, according to the clinic protocol.
02. AT HOME
.webp)
Between visits Clinic-guided maintenance
Patients may use the patch according to a defined schedule, with instructions provided by the clinic.
03. FOLLOW UP
Follow-upTrack usability and repeat use
Pilot partners collect feedback on tolerability, handling, adherence, and reorder potential.
Designed for professional pilot workflows
The ExoGenis pilot kit is designed to support professional handling, protocol consistency, follow-up, and repeat-use evaluation.
Illustrative pilot economics
.svg)
100
eligible patients / month
.svg)
.svg)
30 %
pilot adoption assumption
.svg)
€100–150
indicative price per application
llustrative gross revenue opportunity
€3,000 – €4,500 / month
Based on sample adoption and pricing assumptions.
Actual use, pricing, and margins to be validated.
Not just a patch: a structured, clinic-guided protocol designed to validate repeat use, workflow fit, and reorder potential.
- Why Partner With Us
Partnership value proposition
ExoGenis partners with a limited number of aesthetic and dermatology clinics to validate a new delivery layer, designed to support existing injectable and device-based treatments where injections are not optimal.
Clinical Differentiation
Ready-to-deploy protocols with training and implementation support.
Operational Efficiency
Increase patient throughput without increasing procedure time.
Protocol Integration
Structured training and implementation support.
Early Access & Co-development
Early access to a new treatment category with performance data participation.
- 2026 Co-Creation Partnership
The future of injection-free biologics
We are selecting 3–5 elite clinics to co-develop high-efficacy protocols. Bridge the gap between breakthrough technology and clinical excellence.
Month 0
01
Partner onboarding
Month 1
02
Protocol integration
Month 2
03
Controlled pilot deployment
Month 3
04
Performance review & scale decision
Willingness to participate in structured data collection and feedback during pilot phase
- protocol
ExoGenis maintenance protocol
Designed for clinic deployment and structured pilot testing.
When it’s used
- Post-procedure (laser, RF, injectables)
- Between treatment sessions
- Ongoing maintenance programs
How it’s sold
- 4–12 treatment programs
- Add-on or standalone
- Continuation of clinical results
Why it works commercially
- Designed for recurring usage per patient
- No additional chair time
- Fits existing workflows
- 4–12 applications per treatment cycle
- 2026 Launch
Is your clinic a good fit?
We're looking for forward-thinking clinics that share our commitment to innovation and patient care excellence.
- Perform injectable or device-based treatments
- Work with biologic actives (exosomes, peptides, growth factors)
- Want structured maintenance protocols
- Value clinical differentiation
Adds a new
revenue-generating treatment layer
Integrates seamlessly into existing clinic workflows
Extends the clinical toolkit without replacing injectables or devices.
Extends and enhances treatment outcomes between visits
Supports maintenance, recovery, and biologic support between major procedures.
Fits real clinical workflows
Non-injectable, low-burden, and suitable for repeat or adjunct use.
High-margin recurring revenue stream
Revenue depends on protocol design, pricing, and patient adoption - validated during pilot phase.
- LIMITED EARLY ACCESS
Partnership application
ExoGenis is currently onboarding a limited number of clinics and strategic partners for early collaboration, validation dialogue, and future commercial access.
We are especially interested in dermatology, regenerative aesthetics, and biologic-focused clinical workflows.
*Developed in collaboration with clinical, academic, and biologic delivery partners including DTU and international validation collaborators.